Troubling recent reports reveal the emergence of new omicron subvariants that not only evade AstraZeneca’s Evusheld, the antibody drug authorized to prevent Covid infection, but also the sole antibody drug that has retained effectiveness as treatment for Covid, Eli Lilly’s bebtelovimab.
Doctors have cautioned that should Laura get Covid, this could aggravate her autoimmune disease and lead to catastrophic kidney damage.
Evusheld is a long-acting antibody injection given every six months that studies have suggested provides a robust buffer to the immunosuppressed.
For now, immunocompromised people are anxiously watching the pandemic forecast to see if the subvariants that research indicates evade monoclonal antibodies will become predominant.
“If fewer people are prescribed Evusheld,” she said, “there’s less incentive for drug companies to start developing newer therapeutics.